Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
Status:
Not yet recruiting
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
This is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to
evaluate the safety and efficacy of KL001 injection solution in hemophilia B subjects with ≤2
IU/dl residual FIX levels.
Phase:
Early Phase 1
Details
Lead Sponsor:
Affiliated Hospital of Guangdong Medical University